SPOTLIGHT: Biolex touts hep C data

Biolex Therapeutics says that its Phase IIa trial of Locteron for chronic hepatitis C demonstrated positive results. A combination of the highest dose of Locteron evaluated and the antiviral drug ribavirin achieved an early virologic response in 100 percent of the hepatitis C patients treated. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.